Abstracts

Submit Now

Join Over 2,500+ International Delegates at ISCT 2024 Vancouver to Gain Unparalleled Exposure for Your Research.

.

Present and Network with Decision-Makers Including C-Suite, Directors, and Managers of Leading Organizations and Labs in the Global Cell and Gene Therapy Space.

.

THREE WAYS TO SHOWCASE YOUR WORK!

.

ISCT 2024 Vancouver will feature a large Poster Hall open to delegates throughout the meeting.

In addition, ISCT will host two dedicated poster networking receptions during which all meeting delegates gather in the Poster Hall to review research, discuss findings and network with presenters.

48 high-scoring abstracts will be invited to give a 10-minute presentation of their work at one of the 8 oral abstract sessions. 

Oral abstract sessions are well-attended attracting over 200 delegates.

Thirty high-scoring abstracts will be invited to present their abstract as an elevator pitch and compete for the Best Elevator Pitch Award.

Presenters will have 2 minutes to summarize their research and its impact on the field.

.

.

WHY SUBMIT TO ISCT 2024?

A Truly Translational Focus on a Global Platform
Whether you focus on basic science and preclinical studies, clinical investigations, manufacturing, regulatory, quality, policy, ethics, or commercialization, your work is vital to advancing the field of cell and gene therapy. ISCT is the place for you to discuss your research with a global community of experts across the translation field.    

Showcase Your Research  - Get Feedback, Collaborate
Be considered for an oral abstract, elevator pitch presentation, or poster presentation and promote your work to global leaders in the cell and gene therapy sector.  Gain exposure to key opinion leaders, potential collaborators, future employers, and expand your professional network.   

Publish Your Work
Accepted abstracts will be published in a special supplement of Cytotherapy, the official journal of ISCT.  With a 5-year Impact Factor of 5.0 and a global readership, Cytotherapy represents an excellent platform to highlight your work to a translational audience. Many studies first presented at ISCT Annual Meetings go on to be published as full-length articles.

Qualify for Awards
ISCT recognizes outstanding abstracts and presentations. AT ISCT 2023 Paris, 15 winners were awarded a combined total of $16,000. Submit an abstract and join ISCT to qualify!

Launch Your Career
ISCT is invested in the future of our sector and has created exclusive opportunities for Early Stage Professionals to present their work at ISCT 2024. Students, recent grads, and postdocs are encouraged to submit.

Submit Now

KEY DATES

 

ABSTRACT SUBMISSIONS CLOSE

JANUARY 16, 2024

 

NOTIFICATION OF ACCEPTANCE AND AWARDS

FEBRUARY 13, 2024

 

LATE BREAKING ABSTRACT SUBMISSION OPEN

FEBRUARY 26 - MARCH 4, 2024

 

ACCEPTED ABSTRACT RSVP AND REGISTRATION DEADLINE 

MARCH 12, 2024


ABSTRACT CATEGORIES

  • Mesenchymal Stem/Stromal Cells
  • Hematopoietic Stem/Progenitor Cells and Engineering
  • Immunotherapy (CAR-T, T Reg, NK Cells etc.)
  • Exosomes/EVs
  • iPSC
  • Gene Editing/Gene Therapy
  • Tissue Engineering
  • Embryonic, Organ and Other Tissue Specific Stem Cells
  • Process Development and Manufacturing
  • Regulatory Affairs, Quality Systems, Policy and Ethics


Full List of Abstract Categories

AWARDS

  • Top Scoring Abstract Award ($1,500 USD)
  • Best Poster Award ($1,500 USD) 
  • Early Stage Professionals Awards ($1,000 USD)
    • 3 available
  • Technologist Awards ($1,000 USD)
    • 3 available
  • Top Scoring Emerging Economies Abstract Award ($1,000 USD) 
  • Best Elevator Pitch Abstract Award ($1,000 USD)
  • ESP Rookie of the Year Award ($500 USD)

More awards to be announced.

Eligibility Criteria: Individuals must be presenting an abstract at ISCT 2024 and hold a current ISCT membership.

Publication and Fees

Accepted abstracts will be published in a supplemental version of Cytotherapy, the official journal of ISCT. 
There are no fees associated with submitting an abstract.  Those presenting abstracts will be responsible for their own registration expenses.  


Avoidance of Marketing or Promotion
ISCT requests that presenters avoid the use of trade names and logos for drugs, devices and/or instrumentation in these scientific sessions and to use generic names, where possible. Presentation content will be well-balanced, will be based on generally accepted scientific principles and methods, and will not promote a commercial interest.

Guidelines and Policies

  • To qualify for submission under the late-breaking abstract category, abstracts must contain novel late-breaking data not available during initial submission period.
  • The abstract body cannot exceed 2500 characters, exclusive of the title, author block, images, and tables
  • Note that spaces count as characters
  • Abstracts must be submitted via the online Abstract Submission System. Abstracts will NOT be accepted by email, mail, or fax
  • ISCT may reject abstracts that are considered inappropriate for any reason. Abstracts, once submitted, can only be withdrawn from publication no later than March 12, 2024. If not withdrawn by this deadline, All accepted abstracts will be published in the final program and abstract supplement
  • Abstract presenters MUST be registered for the meeting. For those requiring acceptance notifications before registering, ISCT 2024 will allow up to two weeks after acceptance for these individuals to register
  • Abstracts submitted to the ISCT 2024 Annual Meeting are embargoed from the time of submission.
  • For the abstract to be eligible for presentation at the ISCT 2024 Annual Meeting, information contained within, as well as additional data and information to be presented about the content, may not be published elsewhere or made public before the abstract has been published/presented at the ISCT 2024 Annual Meeting.
  • Authors must notify ISCT if, after the submission deadline, the submitted abstract is accepted for publication elsewhere and will be published before the ISCT 2024 Annual Meeting. Publication before the meeting may result in the abstract being removed from the conference.
  • If the Embargo Policy is violated, the abstract may be withdrawn by ISCT from presentation at the ISCT 2024 Annual Meeting and from publication in the abstract supplement.

*An embargo means that information from any abstract or presentation may not be announced,
publicized, or distributed before the embargo date and time.

ISCT generally does not accept encore abstracts unless there are substantial data updates. However, exceptions may be granted upon written request to vanessaho@isctglobal.org, provided your request includes a clear justification for the encore abstract (e.g. if the ISCT audience significantly differs from the initial presentation).

* An encore abstract is the resubmission of an original abstract that has previously been presented at another conference